Novo Nordisk: New study directly comparing insulin delivery devices shows that Next Generation FlexPen® has a significantly lower injection force than SoloStar® and KwikPen®
Novo Nordisk: New study directly comparing insulin delivery devices shows that Next Generation FlexPen ® has a significantly lower injection force than SoloStar ® and KwikPen ®
New data published this week in Expert Opinion Pharmacotherapy has revealed that Next Generation FlexPen® , Novo Nordisk’s prefilled insulin delivery device, has a significantly lower injection force than two other devices, SoloStar® and KwikPen® .1,2,3 Previous studies show that people with diabetes prefer a lower injection force.4,5
The study revealed that the injection (dose) force of Next Generation FlexPen® was 12–25% lower than SoloStar® and 35–41% lower than KwikPen® .1 In addition to the reduced injection force, this study and others have shown that Next Generation FlexPen® has advantages over SoloStar® and KwikPen® in providing improved accuracy.1,6,7
“Patients with diabetes generally prefer an insulin device with a lower injection force because it provides significantly less discomfort when injecting, especially for patients with impaired manual dexterity,” said Professor Andreas Pfützner, Institute for Clinical Research and Development, Mainz, Germany. “It is vitally important for the sake of compliance and individual satisfaction that patients with diabetes are comfortable with their insulin device as it is something they have to use on a daily basis.”
Next Generation FlexPen® has been available in some countries from late 2008 and is continuing to be launched in countries around the world. It has built upon the high standards set by FlexPen® . New features include 30% less force when injecting, coloured cartridge holders, labels and packaging to aid insulin type identification for patients and an innovative simple and easy needle attachment with a ‘Just twist’ mechanism which allows the NovoTwist™ needle to be attached (to be launched from June 2009).5 This makes the device the first pen to be designed for use with a new generation of needles, which have a patented state-of-the-art attachment interface. These features provide improved convenience and ease of use for people with diabetes.4,5
The study compared the dose forces of Next Generation FlexPen® , SoloStar® and KwikPen® by injecting 20U of insulin using two different gauge needles (NovoFine® 32G and BD Micro-fine™ 31G). Pens of each type were tested at injection speeds of 3.3, 5.0 and 8.3mm/sec. At all three injection speeds and with both needles, Next Generation FlexPen® had a significantly lower average injection force than either SoloStar® or KwikPen® , whilst KwikPen® had the highest mean injection force. Furthermore, the injection force with all three pens was lower when the NovoFine® 32G needle was used as opposed to the BD Micro-fine™ 31G.
About Next Generation FlexPen ®
FlexPen® is the world’s most widely used prefilled insulin pen, trusted daily by more than three million people worldwide.8,9 Next Generation FlexPen® represents the latest advance in prefilled insulin pens from Novo Nordisk, designed to be simple and convenient to use, and helping to reduce the burden of living with diabetes.
Next Generation FlexPen® is a result of more than 25 years of research and development of insulin delivery systems undertaken since Novo Nordisk invented the insulin pen. Compared to other insulin delivery devices that have to be manually loaded with insulin cartridges, prefilled pens are ready to use, eliminating the step of loading insulin into the delivery device. Next Generation FlexPen® features a single-step dose-setting mechanism, portability and a discreet ‘non-medical’ appearance.
With Next Generation FlexPen® it is not possible to set a dose larger than that remaining in the pen. It permits dose corrections without loss of insulin, and provides doses in one-unit increments up to 60 units per injection (each pen contains 300 units in total). The dose scale on Next Generation FlexPen® automatically returns to zero after injection to allow visual confirmation of dose delivery.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,900 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For more information, visit novonordisk.com.
References
1) Asakura T et al. Evaluation of injection force of three insulin
delivery pens. Expert Opin Pharmcother
. DOI
10.1517/14656560903018929. Posted online on 26 May 2009:
http://www.informapharmascience.com/toc/eop/0/0
2) SoloStar® , a prefilled injection device, is a registered trademark of Sanofi-Aventis.
3) KwikPen® , a prefilled injection device, is a registered trademark of Humalog.
4) Sommavilla B et al. Safety, simplicity and convenience of a modified prefilled insulin pen. Expert Opin Pharmacother 2008; 9(13): 2223-32.
5) Pfützner A et al. Prefilled insulin device with reduced injection force: patient perception and accuracy. Curr Med Res Opin 2008; 24(9): 2545-2549.
6) Rissler J et al. Evaluation of the injection force dynamics of a modified prefilled insulin pen. Expert Opin. Pharmacother 2008; 9(13): 2217-2222.
7) Weise A et al. Comparison of the dose accuracy of prefilled insulin pens. J Diabetes Sci Tech 2009; 3(1): 149-53.
8) Estimated number of patients using FlexPen® , based on worldwide sales in number of packs sold, IMS worldwide data Q3’08 and Daily Defined Dosage (DDD) for insulin as issued by WHO.
9) Reimer T et al. Instruction time, Intuitiveness and Patient Acceptance of a Prefilled and a Reusable Insulin Delivery Device – The NovoMix® 30 FlexPen® and the HumaPen® Luxura™. Clin. Ther. 2008; 30(12):2252-62.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Contact:
Novo Nordisk A/S
Media:
Elin K Hansen
Tel: (+45)
4442 3450
ekh@novonordisk.com
or
In
North America:
Ambre Morley
Tel: (+1) 609 987 5898
abmo@novonordisk.com
or
Investors:
Mads
Veggerby Lausten
Tel: (+45) 4443 7919
mlau@novonordisk.com
or
Kasper
Roseeuw Poulsen
Tel: (+45) 4442 4471
krop@novonordisk.com
or
Hans
Rommer
Tel: (+1) 609 919 7937
hrmm@novonordisk.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin25.6.2025 07:00:00 CEST | Press release
Systemic Sclerosis (SSc) is a life-threatening autoimmune disease that causes severe inflammation and fibrosis, while Chronic Pruritus of Unknown Origin (CPUO) is characterized by a persistent, chronic itch with an unknown cause1-3 Nemolizumab is the first approved monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31. It is approved for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world4-6 IL-31 is a neuroimmune cytokine that is involved in inflammation and fibrosis – both hallmarks of SSc – and drives itch, a key symptom of CPUO1,3,4 Enrollment for Galderma’s phase II studies of nemolizumab is planned to begin in H2 2025 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of nemolizumab in treating patients living with Systemic Sclerosis (SSc) and C
MSCI Announces Results of the MSCI 2025 Market Classification Review24.6.2025 23:55:00 CEST | Press release
MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today the results of the MSCI 2025 Market Classification Review. Select highlights of this year’s review includes MSCI: Extending the consultation on a potential reclassification of Bulgaria from Standalone to Frontier Market status Continuing to monitor the implementation and market adoption of measures to enhance the accessibility of the Korean equity market, to determine whether these measures have replicated the outcomes of fully operational offshore FX markets such as those found in Developed Markets Providing updates on the market classification status of Greece Continuing to monitor the market accessibility of the Bangladesh equity market “MSCI is committed to ensuring that our market classifications reflect the evolving realities of global accessibility and investability,” said Raman Aylur Subramanian, Head of Index R&D. “In 2025, we have see
Jørgen Vig Knudstorp Nominated to Join NIKE, Inc. Board of Directors24.6.2025 22:15:00 CEST | Press release
NIKE, Inc. (NYSE:NKE) today announced Jørgen Vig Knudstorp has been nominated for election to its Board of Directors at the Company’s 2025 annual meeting of shareholders, to be held on September 9, 2025. Mr. Knudstorp was President and Chief Executive Officer of the LEGO Group (“LEGO”) from 2004 to 2016, Executive Chair of LEGO Brand Group from 2017 to 2023 and currently serves as Deputy Chair of the LEGO Foundation. He previously held various leadership positions at LEGO from 2001 to 2004. “Jørgen’s strong global experience with brand and digital marketing, strategy, and consumer products, as well as his development and fostering of culture and values, will make him an excellent addition to our board,” said Mark Parker, Executive Chairman of NIKE, Inc. “We look forward to working with Jørgen during an exciting time for NIKE where we will unlock our next chapter of growth through innovative product and distinctive brand storytelling across an integrated marketplace.” Prior to joining L
NetApp Appoints Disruptive Innovator Syam Nair as Chief Product Officer, Underscoring its Commitment to Bold Product Vision24.6.2025 22:05:00 CEST | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced the appointment of Syam Nair as its new Chief Product Officer (CPO), effective Monday, July 7, 2025. Nair succeeds Harv Bhela, who concluded his tenure in June following a successful chapter of product leadership. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250624871234/en/ Syam Nair, Chief Product Officer at NetApp Nair is a former Salesforce and Microsoft executive renowned as a maverick innovator in the industry, bringing over 25 years of experience in scaling cloud platforms and driving hyper-growth. In his new role, Nair will lead NetApp’s product and engineering teams to accelerate innovation in hybrid cloud and AI offerings and advance NetApp’s strategic vision for data-driven business growth. “I am thrilled to welcome Syam to NetApp’s leadership team. He joins us at a time when our customers are looking to NetApp to help them deli
Mirion Technologies and Westinghouse Partner to Drive Digital Innovation in Nuclear Instrumentation Systems24.6.2025 22:04:00 CEST | Press release
Based on Mirion’s proTK™ Product Line, the Newly Designed Solution Aims to Reduce Burden and Enhance Performance in Nuclear Power Plants. Mirion Technologies (NYSE: MIR), a leading provider of advanced radiation safety solutions, and Westinghouse Electric Company LLC, a leading supplier of nuclear plant instrumentation and control systems, have announced a strategic partnership to provide digital Ex-core Nuclear Instrumentation Systems (NIS) based on the high-performing Mirion proTK product line. This collaboration aims to alleviate operator and maintenance burdens, enhance performance, and ensure sustained operation success. This digital NIS upgrade solution is offered exclusively through Westinghouse for both Westinghouse and Combustion Engineering designed PWRs worldwide. This initiative leverages Mirion’s proTK product line to upgrade existing analog neutron flux monitoring drawers, which were originally designed in the 1960s, to a state-of-the-art digital system. The Mirion proTK
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom